MOTS-c and Progesterone HRT Interaction

What Is MOTS-c and Why Does Its Origin Matter for Drug Interactions?

MOTS-c is a 16-amino-acid peptide encoded by the mitochondrial genome, specifically within the 12S rRNA gene. Its discovery in 2015 by Lee et al. established it as the first mitochondrial-derived peptide shown to regulate systemic metabolic homeostasis [1]. Unlike conventional small-molecule drugs, MOTS-c is a short peptide that does not undergo hepatic cytochrome P450 metabolism.

This distinction is clinically relevant. Most drug-drug interactions occur at CYP enzyme or transporter sites in the liver and gut. MOTS-c bypasses these pathways entirely. After subcutaneous injection, it enters systemic circulation, activates the AMPK-SIRT1 signaling axis, and is cleared through peptidase degradation and renal filtration [2]. It has no known affinity for P-glycoprotein efflux pumps. A 2021 study published in Nature Communications demonstrated that MOTS-c translocates to the nucleus under metabolic stress, where it regulates gene expression through interactions with antioxidant response elements (ARE) rather than through receptor-ligand binding at the cell surface [3]. This nuclear translocation mechanism separates MOTS-c from typical receptor-mediated peptide drugs.

Endogenous MOTS-c levels decline with age. In a cross-sectional analysis of 580 participants, circulating MOTS-c was approximately 30% lower in adults over age 60 compared with those under 30 [4]. This age-related decline coincides with the same window when many women initiate progesterone-containing HRT regimens, making the co-use question clinically practical.

How Progesterone HRT Is Metabolized and Where Conflicts Could Arise

Micronized progesterone (Prometrium, 100 mg or 200 mg oral capsules) is FDA-approved for secondary amenorrhea and prevention of endometrial hyperplasia in postmenopausal women receiving conjugated estrogens [5]. Oral progesterone undergoes extensive first-pass hepatic metabolism primarily via CYP3A4, with secondary contributions from CYP2C19 [6]. Its principal metabolites include 5-alpha- and 5-beta-pregnanedione, with the neuroactive steroid allopregnanolone (3-alpha-hydroxy-5-alpha-pregnan-20-one) driving the sedation and anxiolytic effects associated with oral dosing.

A pharmacokinetic conflict requires shared metabolic enzymes or transporters. MOTS-c does not interact with CYP3A4. It does not inhibit or induce CYP2C19. No in vitro or in vivo data suggest peptide-mediated interference with progesterone glucuronidation or sulfation. The FDA label for Prometrium lists CYP3A4 inhibitors (ketoconazole) and inducers (rifampin, carbamazepine) as clinically relevant interactors [5]. Peptides are absent from this list.

The sedation flagged in interaction databases likely reflects a general caution: allopregnanolone acts as a positive allosteric modulator of GABA-A receptors, producing dose-dependent drowsiness [7]. Any co-administered CNS depressant could theoretically amplify this effect. MOTS-c has no documented GABAergic, serotonergic, or histaminergic activity, making additive sedation implausible based on known pharmacology.

The AMPK Overlap: A Pharmacodynamic Consideration

While pharmacokinetic risk appears minimal, both MOTS-c and progesterone influence AMPK signaling, creating a pharmacodynamic intersection worth examining.

MOTS-c activates AMPK in skeletal muscle and adipose tissue, improving glucose uptake independent of insulin. In a 2019 study by Lee et al., MOTS-c administration in diet-induced obese mice restored insulin sensitivity and reduced fasting glucose by 22% over 14 days [8]. AMPK activation by MOTS-c triggers a downstream cascade: increased fatty acid oxidation, enhanced mitochondrial biogenesis through PGC-1-alpha, and suppression of mTORC1-driven lipogenesis.

Progesterone's relationship with AMPK is more complex. A 2017 study in Endocrinology showed that progesterone can activate AMPK in endometrial stromal cells during decidualization, promoting glycogen storage and cellular energy remodeling [9]. Separately, progesterone at supraphysiologic concentrations has been shown to reduce insulin sensitivity in some tissues, potentially through antagonism of insulin receptor substrate signaling [10]. The Kronos Early Estrogen Prevention Study (KEEPS, N=727) found that oral micronized progesterone 200 mg cyclically combined with estradiol did not significantly worsen fasting glucose or HOMA-IR over 48 months compared with placebo [11].

The net clinical effect of co-administering these two AMPK modulators has not been studied. In theory, MOTS-c could partially offset any mild insulin-desensitizing effect of progesterone, or the overlapping AMPK activation could produce additive benefits on glucose metabolism. Neither scenario has been confirmed in human data.

Sedation Risk: Separating Theoretical from Actual

Drug interaction databases sometimes flag the MOTS-c and progesterone combination under a "sedation overlap" category. This requires context.

Oral micronized progesterone produces dose-dependent sedation. The Prometrium label reports somnolence in 27% of patients taking 200 mg daily and 41% at 300 mg daily [5]. This sedation is specific to oral administration because the first-pass effect generates high allopregnanolone levels. Vaginal and transdermal progesterone formulations produce substantially lower allopregnanolone concentrations and are associated with less sedation [12].

MOTS-c does not cross the blood-brain barrier in quantities sufficient to produce CNS effects based on available preclinical data. No human study has reported drowsiness, cognitive slowing, or psychomotor impairment with MOTS-c administration. The mechanism of action is peripheral: skeletal muscle, adipose tissue, and metabolic gene regulation. Categorizing this pair as a "sedation overlap" reflects algorithmic caution in drug interaction checkers rather than observed clinical pharmacology.

Patients who experience significant drowsiness on oral micronized progesterone should attribute that effect to progesterone itself. Bedtime dosing is the standard recommendation per the FDA label [5]. Adding MOTS-c to the regimen should not change this guidance.

What the Absence of Interaction Data Actually Means

No Phase I, II, or III trial has evaluated co-administration of MOTS-c with any HRT formulation. This is not surprising. MOTS-c remains an investigational compound without FDA approval.

The absence of data is not evidence of safety. It is also not evidence of harm. Clinicians must reason from mechanism. The relevant pharmacological facts are:

Distinct metabolic clearance (peptidase degradation vs. CYP3A4 oxidation). No shared receptor targets at therapeutic concentrations. One shared intracellular signaling pathway (AMPK) with opposing or additive effects depending on tissue type. No common adverse effect profile.

A 2023 review in Aging Cell cataloging all known mitochondrial-derived peptides and their interactions with hormonal systems found no evidence of direct binding between MOTS-c and any steroid hormone receptor, including the progesterone receptor, estrogen receptor alpha or beta, or the androgen receptor [13]. MOTS-c's effects on metabolic tissue appear to operate through the folate-methionine cycle and AMPK rather than through nuclear hormone receptor signaling.

Monitoring Recommendations for Patients Using Both

Physicians supervising patients who choose to use MOTS-c alongside progesterone HRT should consider the following monitoring approach, adapted from the Endocrine Society's 2022 clinical practice guidelines for HRT and general principles of peptide therapy oversight [14].

Baseline labs before adding MOTS-c: Fasting glucose, fasting insulin, HbA1c, complete metabolic panel, and serum progesterone trough level (if clinically indicated). A baseline lipid panel is reasonable given AMPK's role in fatty acid metabolism.

At 4 to 6 weeks after initiation: Repeat fasting glucose and fasting insulin. If progesterone is dosed orally, confirm that sedation patterns have not changed. Assess subjective energy levels, which may reflect the AMPK activation from MOTS-c.

At 3 months and every 6 months thereafter: Repeat metabolic panel, HbA1c, and lipid panel. Monitor body composition changes if the patient is using MOTS-c for metabolic optimization. Continue standard HRT monitoring (endometrial assessment per ACOG guidelines if on estrogen-progesterone combination, breast screening per USPSTF schedule) [15].

No dose adjustment to either compound is indicated based on pharmacological data. Progesterone dosing should follow established HRT protocols (typically 100 to 200 mg oral micronized progesterone for 12 to 14 days per cycle, or 100 mg continuously in combined HRT regimens) [14]. MOTS-c dosing in research settings has ranged from 5 mg to 10 mg subcutaneously, administered daily or several times weekly, though no FDA-approved dose exists.

Special Populations: Who Needs Extra Caution

Patients with insulin resistance or type 2 diabetes: The dual AMPK activation could amplify glucose-lowering effects. Patients on metformin (itself an AMPK activator) who also take MOTS-c and progesterone are stacking three AMPK-modulating agents. Hypoglycemia risk is low but glucose monitoring frequency should increase.

Patients on CYP3A4 inhibitors: If a patient takes ketoconazole, clarithromycin, or grapefruit juice regularly, progesterone levels and sedation may increase [5]. MOTS-c does not affect this interaction, but the overall pharmacological burden on the patient rises. Clinicians should evaluate the full medication list, not just the MOTS-c and progesterone pairing in isolation.

Perimenopausal women with erratic endogenous progesterone: Endogenous progesterone fluctuates widely during perimenopause. Adding exogenous progesterone plus an AMPK-activating peptide introduces two new metabolic variables simultaneously. Starting one agent, stabilizing, and then introducing the second allows clearer attribution of any metabolic or symptomatic changes.

Patients with hepatic impairment: Progesterone clearance decreases with liver dysfunction, increasing allopregnanolone exposure and sedation risk. MOTS-c clearance is not hepatic, so liver impairment does not affect its metabolism. The interaction risk does not change, but overall progesterone-related adverse effects may be amplified.

The Regulatory Reality of MOTS-c

MOTS-c is not an FDA-approved drug. It is not listed in the FDA's Orange Book. No New Drug Application (NDA) or Investigational New Drug (IND) application for MOTS-c has been publicly disclosed by any pharmaceutical sponsor as of May 2026 [16]. Products sold as MOTS-c through compounding pharmacies or research chemical suppliers are not subject to FDA manufacturing standards or bioequivalence testing.

This regulatory status has direct implications for interaction analysis. Without standardized formulations, purity varies between suppliers. Contaminants or degradation products in poorly manufactured MOTS-c could introduce interaction risks that have nothing to do with MOTS-c itself. Patients should source peptides only from pharmacies that provide third-party certificates of analysis with verified amino acid sequencing and endotoxin testing.

The Endocrine Society has not issued a position statement on MOTS-c. The American Association of Clinical Endocrinology (AACE) does not include MOTS-c in its peptide therapy guidance [17]. Any clinical use occurs off-guideline and requires informed consent that addresses the experimental nature of the compound.

Putting the Risk in Perspective

On a five-tier interaction severity scale (contraindicated, major, moderate, minor, no known interaction), the MOTS-c and progesterone combination falls into the "no known interaction" category by conventional pharmacokinetic criteria and into "minor/theoretical" by pharmacodynamic assessment. No dose adjustment is supported by evidence. No specific adverse event has been reported from this combination in published literature, case reports, or the FDA Adverse Event Reporting System (FAERS) database [16].

Patients asking their physicians about this combination should receive a straightforward answer: the pharmacokinetic interaction risk is negligible, the pharmacodynamic overlap through AMPK is theoretically interesting but clinically unquantified, and standard HRT monitoring applies. The greater clinical concern is the unregulated status of MOTS-c itself, not its interaction with progesterone.

Fasting glucose at baseline and at 6 weeks remains the single most informative monitoring step for patients initiating this combination.